Their approach yielded two new compounds that effectively inhibited CDK4/6 while maintaining excellent selectivity for CDK2, demonstrating promise in inhibiting retinoblastoma protein (pRb) phosphorylation in breast cancer cells and exhibiting potential for oral therapeutic applications in breast cancer17. The gene discussed is CDK4; the disease is breast carcinoma.